INTRODUCTIONRecently peripheral nerve block anaesthesia has become popular against general anaesthesia as it is devoid of side effects of intubation and muscle relaxants and systemic haemodynamic changes. This type of anaesthesia is particularly advantageous in case of prolonged orthopedic, plastic reconstructive surgeries and in emergency surgeries where the patients are full stomach, not adequately starving and in high risk patients. This technique not only provides anaesthesia but also postoperative analgesia. 1Peripheral nerve block anaesthesia had many advantages over general anaesthesia such as cost effective, favourable postoperative recovery profile, preserves CNS functions and prevents complications of intubation, laryngoscopy and muscle relaxants. Recently nerve ABSTRACT Background: Peripheral nerve blocks have assumed a prominent role in modern anaesthesia practice as they provide ideal operative conditions without any general anaesthesia or adverse haemodynamic effects. When compared with ropivacaine, levobupivacaine is a newer, safer, longer acting local anaesthetic with rapid onset and prolonged duration of analgesia and similar or more pronounced nerve blocking effects, depending on the concentration. Hence the present study is aimed to compare the effectiveness of 0.5% levobupivacaine and 0.5% ropivacaine in supraclavicular brachial plexus block. Methods: The present study was a prospective, randomized, double blind comparative study of 60 patients with ASA grade I, II of either sex, between the ages 18 years to 60 years. They were enrolled and randomly divided into two groups. Supraclavicular brachial plexus block was given for upper limb surgeries using 0.5% levobupivacaine (Group L) or 0.5% ropivacaine (Group R). The onset of sensory and motor block, their duration, and possible adverse events were recorded and compared for both groups. Results: Significant earlier onset of sensory blockade (p=0.027) and motor blockade (p=0.01), prolonged duration of sensory and motor blockade (p=0.0001) was observed in group of patients receiving levobupivacaine compared to ropivacaine. The time for first rescue analgesia required post operatively was much longer in Group L(13.2333±1.1651hr) as compared to Group R(10.8667±0.91852 hr) and the difference was significant (p=0.0001).Intraoperatively throughout the study heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) were comparable in both the groups and found no statistically significant difference (p >0.05). The heart rate, systolic and diastolic blood pressure for both the groups were compared postoperatively and observed no statistical significant difference (p >0.05). No adverse effects were observed in both the groups. Conclusions: 0.5% levobupivacaine used in supraclavicular brachial plexus block for upper limb surgeries provides rapid onset of sensory and motor blockade and prolonged duration of analgesia compared to 0.5% ropivacaine.
Background and Aims:We studied the efficacy and safety of different total intravenous anesthesia used for pediatric magnetic resonance imaging (MRI).Material and Methods:Children of 1–7 years age (n = 88), undergoing MRI received a loading dose of dexmedetomidine 1 μg/kg over 10 min, ketamine 1 mg/kg, and propofol 1 mg/kg in sequence. University of Michigan Sedation Scale (UMSS) of 3 was considered an acceptable level for starting the scan. Rescue ketamine 0.25–0.5 mg/kg was given if UMSS remained <3. After the loading dose of drugs, some children attained UMSS = 4 or progressive decline in heart rate, therefore, did not receive any infusion. The rest received either dexmedetomidine (0.7 μg/kg/h) (n = 35) or propofol (3 mg/kg/h) (n = 38) infusion for maintenance. Ketamine 0.25 mg/kg was used as rescue. Sedation failure was considered if either there was inability to complete the scan at the pre-set infusion rate, or there was need for >3 ketamine boluses or serious adverse events occurred. Statistical Package for Social Sciences 20 was used for analysis.Results:Initiation of scan was 100% successful with median induction time of 10 min. Maintenance of sedation was successful in 100% with dexmedetomidine and 97.4% with propofol infusion. Recovery time (25 min v/s 30 min), discharge time (35 min v/s 60 min), and total care duration (80 min v/s 105 min) were significantly less with propofol as compared to dexmedetomidine (P = 0.002, 0.000, and 0.000, respectively). There were no significant adverse events observed.Conclusion:Dexmedetomidine 1μg/kg, ketamine 1 mg/kg, and propofol 1 mg/kg provide good conditions for initiation of MRI. Although dexmedetomidine at 0.7μg/kg/h and propofol at 3 mg/kg/h are safe and effective for maintenance, propofol provides faster recovery.
Achalasia, a benign motility disorder of the esophagus, results in incomplete relaxation of the lower esophageal sphincter (LES) and absent peristalsis. Patients experience dysphagia, regurgitation, chest pain, weight loss, and heartburn. Pharmacological therapy has been unsatisfactory and definitive treatment has focused on mechanical disruption of the tight LES. Peroral endoscopic myotomy (POEM) is a safe and minimally invasive modality regarded as the first-line management of all types of achalasia. POEM is performed under general anesthesia with endotracheal intubation using an orally inserted gastrointestinal endoscope. Briefly, POEM involves endoscopic creation of a mid-esophageal submucosal incision, creation of a submucosal tunnel with the endoscope, and then a myotomy of distal circular muscles with a Triangular Tip electrosurgical (TT) knife, resulting in relaxation of the achalasia. We, hereby report a case of a patient with Achalasia Cardia Type II posted for POEM procedure under General Anaesthesia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.